224 related articles for article (PubMed ID: 37700348)
1. Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial.
Jiang H; Makelike K; Chen B; Xi M; Li Q; Hu Y; Zhu Y
Radiat Oncol; 2023 Sep; 18(1):150. PubMed ID: 37700348
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma.
Zhu Y; Zhang W; Li Q; Li Q; Qiu B; Liu H; Liu M; Hu Y
J Cancer; 2017; 8(18):3657-3666. PubMed ID: 29151952
[No Abstract] [Full Text] [Related]
3. Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
Zhang P; Xi M; Li QQ; Hu YH; Guo X; Zhao L; Liu H; Liu SL; Luo LL; Liu Q; Liu MZ
Oncotarget; 2016 Jul; 7(28):44686-44694. PubMed ID: 27183916
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
[TBL] [Abstract][Full Text] [Related]
6. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
Hsieh JC; Chiang PC; Hung TM; Chao YK; Kuo YC; Wen CT; Su PJ; Peng MT; Chen HW; Liu HL; Chang HK; Wu MH; Wang HM
Cancer Med; 2021 Dec; 10(23):8300-8309. PubMed ID: 34706159
[TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
Zhao T; Chen H; Zhang T
Med Oncol; 2012 Dec; 29(5):3017-23. PubMed ID: 22476809
[TBL] [Abstract][Full Text] [Related]
9. The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial.
Luo Y; Cai B; Li B; Liu F; Du L; Zhao D; Fan W; Meng L; Zhang X; Ma L
Technol Cancer Res Treat; 2022; 21():15330338221109974. PubMed ID: 35770295
[No Abstract] [Full Text] [Related]
10. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
11. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
13. A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma.
Xia X; Liu Z; Cai B; Di X; Sun X; Ge X
Cancer Radiother; 2021 Feb; 25(1):39-44. PubMed ID: 33419607
[TBL] [Abstract][Full Text] [Related]
14. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
15. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
[TBL] [Abstract][Full Text] [Related]
16. A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence.
Liu Q; Xia Y; Chen Y; Zhang J; Deng J; Zhao K
Radiat Oncol; 2020 Apr; 15(1):75. PubMed ID: 32268925
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
[TBL] [Abstract][Full Text] [Related]
19. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Chen Y; Ye J; Zhu Z; Zhao W; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Jia H; Lu S; Zhang Z; Zhao K
J Clin Oncol; 2019 Jul; 37(20):1695-1703. PubMed ID: 30920880
[TBL] [Abstract][Full Text] [Related]
20. Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.
Chen B; Li Q; Li Q; Qiu B; Xi M; Liu M; Hu Y; Zhu Y
Oncologist; 2020 Apr; 25(4):308-e625. PubMed ID: 31880371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
